Understanding Your Child's DMD Mutation and Treatment Eligibility
The exact DMD gene change matters. How deletions, duplications, and point mutations differ, and why the specific mutation shapes eligibility for some treatments.
The specific change in the dystrophin gene, often just called the mutation, is one of the most important pieces of information a Duchenne muscular dystrophy family can have. It confirms the diagnosis, informs genetic counselling, and increasingly determines which treatments a child may be eligible for. Understanding the main types of mutation helps make sense of this.
This post explains DMD mutation types and why they matter. Genetic results are interpreted with the care team and a genetic counsellor.
How the dystrophin gene goes wrong
The dystrophin gene is very large, and Duchenne can be caused by several kinds of change. For background on the gene, see the dystrophin gene explained. The main categories are deletions, where a piece of the gene is missing, duplications, where a piece is repeated, and smaller changes such as point mutations, including nonsense mutations. (Dystrophinopathies, PubMed)
Deletions are the most common, but all of these types can cause Duchenne.
Why the type and location matter
It is not only the type of change but where it falls in the gene that matters. Whether the change disrupts the reading of the gene, and exactly which parts are affected, influences how much dystrophin, if any, is made. This partly explains the difference between Duchenne and the milder Becker muscular dystrophy.
This is also why two children with deletions can have different outcomes.
Mutation-specific treatments
A major reason the exact mutation now matters is that some treatments only work for particular mutations. Exon-skipping therapies, for example, are designed for specific deletions amenable to skipping a particular exon, and are approved only for those. (Eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping, PROMOVI trial, PubMed) For background, see exon-skipping therapies in DMD.
Other approaches target other mutation types, which is why eligibility depends on the specific genetic result.
Knowing your child’s mutation
Because eligibility for some therapies and trials depends on it, families benefit from knowing their child’s exact mutation, usually described in the genetic report. Keeping this information accessible is useful. For background, see organizing medical information: a care binder for Duchenne families and joining a clinical trial: what it means for a Duchenne family.
A genetic counsellor can explain what a specific result means. For background, see genetic counseling for Duchenne families.
What it means for the family
The mutation also carries information for the wider family, since it can be traced in carrier testing. For background, see DMD carrier mothers and genetic counseling for Duchenne families.
Knowing the mutation supports both treatment decisions and family planning.
What is still uncertain
The link between specific mutations and outcomes is not fully understood, and mutation-specific treatments are a fast-moving field with more in development. For background, see the DMD research pipeline. What is consistent is that the exact mutation is key information worth understanding and keeping.
For related reading, see the dystrophin gene explained, exon-skipping therapies in DMD, genetic counseling for Duchenne families, Becker muscular dystrophy: a closer look, and the reported piece Two Mothers, Two Realities.
Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.